
|Videos|August 10, 2016
The Mechanism of Action of Durvalumab in the Treatment of Urothelial Bladder Cancer
Author(s)Saeed Rafii, MD, PhD
Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses the mechanism of action of the PD-1 antibody durvalumab in a phase I/II dose-escalation and dose-expansion study in the treatment of patients with metastatic urothelial bladder cancer. He also discusses the next steps in this line of research.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































